<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715048</url>
  </required_header>
  <id_info>
    <org_study_id>HS-19-00455</org_study_id>
    <nct_id>NCT04715048</nct_id>
  </id_info>
  <brief_title>Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines</brief_title>
  <official_title>Split-Face Study Comparing OnabotulinumtoxinA (Botox) and PrabotulinumtoxinA (Jeuveau) in Treating Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and side effects of Botox and Jeuveau&#xD;
      for glabellar lines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients given consent will&#xD;
      receive Botox on one side of their face and Jueveau on the other. A random number generator&#xD;
      will generate a list of 20 combinations of &quot;1,2&quot; or &quot;2,1&quot;. &quot;1,2&quot; means the Botox&#xD;
      (onabotulinumtoxin A) will be placed on the right side and &quot;2,1&quot; means that the Botox will be&#xD;
      placed on the left. The other side will be injected with PrabotulinumtoxinA. 8-10 units will&#xD;
      be injected into the designated glabella in 3 sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The two different neurotoxins will be drawn into identical appearing syringes by an unblinded investigator. The injector will be a blinded investigator and will not know which syringe has which neurotoxin. There is no difference in appearance of the product when in a standardized syringe. The PI and co-investigator will be graders of these images and will be blinded during the grading process.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Movement on a 10 point Frown Movement Scale at 3 weeks</measure>
    <time_frame>3 weeks</time_frame>
    <description>10-point scale created by the investigator assessing movement of glabellar lines. Possible scores range from 0 (no movement) to 10 (movement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days to onset of neurotoxin</measure>
    <time_frame>Up to 2-4 days</time_frame>
    <description># of days until neurotoxin begins decreasing movement on each side</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bruising from the injection on a scale of 1-10</measure>
    <time_frame>Up to 2-4 days</time_frame>
    <description>Post injection bruising measured on a scale from 0 (no bruising) to 10 (most possible bruising) created by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain from the injection on a scale of 1-10</measure>
    <time_frame>Up to 2-4 days</time_frame>
    <description>Post injection pain will be measured on a scale from 0 (no pain) to 10 (most possible pain) created by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache from the injection on a scale of 1-10</measure>
    <time_frame>Up to 2-4 days</time_frame>
    <description>Post injection headache will be measured on a scale from 0 (no pain) to 10 (most possible pain) created by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement on a 10 point Frown Movement Scale at 3 weeks</measure>
    <time_frame>3 weeks</time_frame>
    <description>Patients grade their own movement of glabellar lines using a 10-point scale created by the investigator. Possible scores range from 0 (no movement) to 10 (movement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glabellar lines on the Merz Score (0-4)</measure>
    <time_frame>At baseline and 3 weeks</time_frame>
    <description>The Merz Score is a 5 point scale. The Merz Score will be used to grade glabellar lines at rest and frown at both baseline and the 3 week visit. Change will calculated from the 3 week visit compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Onabotulinumtoxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-10 units of Botox will be injected in the glabellar lines in one side of the face in 3 different locations. This injection will happen once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prabotulinumtoxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-10 units of Jeuveau will be injected in the glabellar lines in the other side of the face in 3 different locations. This injection will happen once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrabotulinumtoxinA</intervention_name>
    <description>Glabellar line correction</description>
    <arm_group_label>Prabotulinumtoxin A</arm_group_label>
    <other_name>Jeuveau</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onabotulinum toxin A</intervention_name>
    <description>Glabellar line correction</description>
    <arm_group_label>Onabotulinumtoxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Willingness to participate in the study and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to follow up for study duration&#xD;
&#xD;
          -  Prior neurotoxin injection in the last 4 months&#xD;
&#xD;
          -  Prior surgery to the glabellar area&#xD;
&#xD;
          -  Any planned aesthetic procedure to the glabellar area during the study period&#xD;
&#xD;
          -  Cardiac Patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandy Zhang-Nunes, MD</last_name>
    <phone>(800) 872-2273</phone>
    <email>zhangnun@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Preeya Mehta</last_name>
    <phone>(408) 3344842</phone>
    <email>preeyame@usc.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Rzany BJ, Ascher B, Avelar RL, Bergdahl J, Bertucci V, Bodokh I, Carruthers JA, Cartier H, Delmar H, Denfeld R, Gross JE, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Sattler G, Sebastian M, Solish N, Swift A, Trévidic P. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients. Aesthet Surg J. 2020 Mar 23;40(4):413-429. doi: 10.1093/asj/sjz110.</citation>
    <PMID>30951166</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Sandy Zhang-Nunes</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Ophthalmology; Chief of Oculofacial Plastics Services</investigator_title>
  </responsible_party>
  <keyword>Botox, Jeuveau</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

